Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
18.02 USD | +1.81% | -1.10% | -30.98% |
26/04 | CVS Omnicare staff in Las Vegas vote to join new union | RE |
26/04 | Morgan Stanley Adjusts Price Target on Walgreens Boots Alliance to $16 From $20 | MT |
Summary
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The stock, which is currently worth 2024 to 0.15 times its sales, is clearly overvalued in comparison with peers.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- The company is one of the best yield companies with high dividend expectations.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-30.98% | 15.27B | B- | ||
-29.67% | 10.84B | B | ||
-28.54% | 6.06B | B | ||
+7.42% | 6.04B | C | ||
-11.41% | 5.86B | C+ | ||
-0.73% | 4.69B | D- | ||
+52.19% | 4.29B | - | C | |
-9.42% | 3.61B | B | ||
-13.25% | 3.33B | C- | ||
-6.93% | 3.01B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- WBA Stock
- Ratings Walgreens Boots Alliance, Inc.